EyeGene Company Description

EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea.

Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury.

It also develops EG-HZ, which has completed phase 1 clinical trial for the treatment of herpes zoster; EG-HPV which completed Phase 1 clinical trial to treat cervical cancer; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-TB for the tuberculosis vaccine and is in preclinical trial.

In addition, the company offers vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

EyeGene Inc.

Country	South Korea
Founded	2000
Industry	Biological Products, Except Diagnostic Substances
Employees	49
CEO	Won-Il Yoo

Contact Details

Address: 401 Yangcheon-ro Seoul, 16009 South Korea
Phone	82 2 322 1687
Website	eyegene.co.kr

Stock Details

Ticker Symbol	185490
Exchange	KOSDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2836

Key Executives

Name	Position
Won-Il Yoo	Chief Executive Officer
Soobeom Lee	Chief Financial Officer